{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T16:10:04Z","timestamp":1745597404648,"version":"3.40.4"},"reference-count":9,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>Palmar-Plantar syndrome (PPS) is a common side effect of oral capecitabine\u2014a chemotherapeutic agent used as an adjuvant treatment for colorectal cancer. A 66-year-old man suffering from grade II PPS described how Germolene New Skin, a topical healing agent, provided relief from the pain associated with this syndrome and a return to normal function. The patient's observations form the basis for some interesting hypotheses regarding the natural progression of PPS and the potential of New Skin to alleviate pain. Caution must be exercised at this stage as these are single case observations; however, they may be worthy of further exploration in a randomised controlled clinical trial.<\/jats:p>","DOI":"10.1136\/bcr.04.2010.2869","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T15:41:25Z","timestamp":1289403685000},"page":"bcr0420102869","source":"Crossref","is-referenced-by-count":1,"title":["Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome: Figure 1"],"prefix":"10.1136","volume":"2010","author":[{"given":"Arie R","family":"Gafson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Goodkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Begent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2010,11,10]]},"reference":[{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.1","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.2","unstructured":"Cancer therapy evaluation program, common terminology criteria for adverse events, Version 3.0, DCTD, NCI, NIH, DHHS."},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.3","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120000360"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.4","first-page":"1161","article-title":"Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine","volume":"18","author":"Scheithauer","year":"2004","journal-title":"Oncology (Williston Park, NY)"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CCC.2005.s.007","article-title":"Benefits and drawbacks of the use of oral fluoropyrimidines as single agent therapy in advanced colorectal cancer","volume":"5","author":"Cassidy","year":"2005","journal-title":"Clin Colorectal Cancer"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.6","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00004"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2004.06.007"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.8","doi-asserted-by":"crossref","unstructured":"Lee S Lee S Chun Y . Pyridoxine is not effective for the prevention of hand foot syndrome (HFS) associated with capecitabine therapy: results of a randomized double-blind placebo controlled study. ASCO 2007;Abstract 9007.","DOI":"10.1200\/jco.2007.25.18_suppl.9007"},{"key":"2025042508553386000_2010.nov09_1.bcr0420102869.9","doi-asserted-by":"publisher","DOI":"10.1191\/1078155203jp116oa"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.04.2010.2869","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T15:55:43Z","timestamp":1745596543000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.04.2010.2869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":9,"alternative-id":["10.1136\/bcr.04.2010.2869"],"URL":"https:\/\/doi.org\/10.1136\/bcr.04.2010.2869","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2010]]}}}